RCT: In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge compared with usual-care thromboprophylaxis.
5 Aug, 2021 | 09:07h | UTCEditorial: Surviving Covid-19 with Heparin?
Commentaries:
Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t – TCTMD
Commentary on Twitter
In noncritically ill patients with #COVID19, anticoagulation increased the probability of survival to hospital discharge without organ support. https://t.co/3JzKdmL3SB #IDTwitter pic.twitter.com/iDjSelp2HL
— NEJM (@NEJM) August 4, 2021